Results 251 to 260 of about 59,185 (303)

[Vaccination against herpes zoster].

Ugeskrift for laeger, 2021
During their lifetime, 25% of Danes will experience an episode of herpes zoster (HZ). In 15-20% of these 25% HZ will be complicated by postherpetic neuralgia (PHN). The European Medicines Agency has approved two vaccines against HZ, a live attenuated vaccine (ZLV) and a recombinant adjuvanted vaccine (RZV).
Carsten Schade, Larsen, Marie, Helleberg
openaire   +1 more source

Presumed Herpes Zoster Ophthalmicus Reactivation Following Recombinant Zoster Vaccination

Cornea, 2020
Purpose: To report a case of herpes zoster ophthalmicus (HZO) reactivation after recombinant zoster vaccination. Methods: A 78-year-old woman, with a history of HZO 20 years ago, was referred for progressive corneal thinning in her left eye that started 1 week after her second dose ...
Samir, Jabbour, Nakul S, Shekhawat, Ariel, Chen, Fasika A, Woreta   +3 more
openaire   +2 more sources

The herpes zoster subunit vaccine

Expert Opinion on Biological Therapy, 2016
Herpes zoster (HZ) causes severe pain and rash in older people and may be complicated by prolonged pain (postherpetic neuralgia; PHN).HZ results from reactivation of latent varicella-zoster virus (VZV) infection, often associated with age related or other causes of decreased T cell immunity.
openaire   +2 more sources

Preventing Herpes Zoster through Vaccination

Ophthalmology, 2008
The role of the zoster vaccine in the prevention of herpes zoster and its sequelae, including postherpetic neuralgia (PHN) and herpes zoster ophthalmicus.Wide administration of the herpes zoster vaccine in accordance with the recommendations of the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP) will lead ...
openaire   +2 more sources

HERPES ZOSTER AFTER COVID VACCINATION

Revista Ibero-Americana de Humanidades, Ciências e Educação, 2023
Vaccination is an important intervention in preventing the spread of coronavirus (SARS-CoV-2). Messenger RNA vaccines were the first to be commercialized, although cutaneous adverse events have been reported in clinical trials for both vaccines, they have not been well characterized.
Zenaide Paulo Silveira, Rodrigo Daniel Zanoni, Lorran Miranda Andrade de Freitas, Mari Nei Clososki da Rocha, Andre Luiz Faleiro Soares, Maria Emilia Barbosa de Oliveira, Letícia Maia Azevedo, Alexandre Maslinkiewicz, Ana Carolina Messias de Souza Ferreira da Costa   +8 more
openaire   +1 more source

Vaccination for quality of life: herpes–zoster vaccines

Aging Clinical and Experimental Research, 2019
Current vaccination policy in most high-income countries aims to counteract the decline in cell-mediated immunity to varicella zoster virus that occurs with advancing age or immunosuppression. The aim of this review was to describe the burden of illness associated with herpes zoster (HZ) and post-herpetic neuralgia (PHN) risks and their impact on the ...
Pierre-Olivier Lang, Richard Aspinall
openaire   +2 more sources

Varicella–Zoster Vaccine for the Prevention of Herpes Zoster

New England Journal of Medicine, 2007
A 64-year-old man in good general health presents to his internist for a routine examination. In a large clinical trial, the varicella–zoster vaccine reduced the incidence of herpes zoster by 51% and the incidence of postherpetic neuralgia by 67%. Should he receive this vaccine?
David W, Kimberlin, Richard J, Whitley
openaire   +2 more sources

Adjuvanted Herpes Zoster Subunit Vaccine

Future Virology, 2015
This review highlights the characteristics of a candidate herpes zoster (HZ) vaccine (HZ/su, GlaxoSmithKline Vaccines) that consists of 50 μg recombinant glycoprotein E (gE) of varicella zoster virus adjuvanted with AS01B. It is well tolerated and shows a clinically acceptable tolerability profile.
Annelies Aerssens, Geert Leroux-Roels
openaire   +1 more source

[Herpes zoster after varicella-zoster vaccination].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2013
A five-year-old girl, vaccinated against varicella-zoster virus (VZV) presented with clinical symptoms of herpes zoster in the 6th cervical dermatome. A VZV direct immune-fluorescence assay was negative three times but additional genotypical analysis showed a VZV strain genotype 2 (Oka vaccine strain).
M, Fahlbusch, U, Wesselmann, P, Lehmann
openaire   +1 more source

Evaluation of herpes zoster vaccine programme

Drug and Therapeutics Bulletin, 2018
Review of: Amirthalingam G et al. Evaluation of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study. Lancet 2018; 3: e82-90.
openaire   +2 more sources